Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors

Figure 4

(a) The pooled HRs for progression-free survival (PFS) by LMR at baseline stratified on tumor types (RCC, NSCLC, GC, and multiple); (b) LMR cut-off (<2 and ≥2); (c) and countries (eastern countries and western countries); (d) funnel plot for the evaluation of publication bias considering the association between the LMR at baseline and PFS (14 studies).

(a)

(b)

(c)

(d)